Board certified Hematologist-Oncologist, master clinician with passion for innovation in cancer treatment. Currently, Vice President of Clinical Development at Servier Pharmaceuticals overseeing hematology and oncology clinical development programs. Direct hands-on experience developing novel therapeutics in rare oncology indications and leading teams through successful design, planning, and execution of Phase 1 and Phase 3 global pivotal studies. Extensive experience in leading first in human clinical trials within an academic teaching hospital of Harvard Medical School.
While death rates are decreasing, there has been an increase in diagnoses, with an expected increase of almost 50% by 2050. With the growing population — including the elderly population — and the utilization of advanced imaging diagnostics, which detect earlier stages of cancer and/or more indolent forms of cancer, rates could continue to climb.15 February 2022